Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.68 |
| ▸ | HTR6 | P50406 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TNFSF11 | O14788 | 3/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12748623 | 0.85 | AKR1C3 (0.78) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL12748642 | 0.84 | AKR1C3 (0.67) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL948989 | 0.83 | AKR1C3 (0.83) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL1466532 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL12748640 | 0.81 | AKR1C3 (0.56) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL12748630 | 0.80 | AKR1C3 (0.78) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL12748306 | 0.80 | AKR1C3 (0.78) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL29414776 | 0.80 | AKR1C3 (0.78) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL947625 | 0.80 | AKR1C3 (0.78) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 | |
| SCHEMBL947655 | 0.80 | AKR1C3 (0.72) | AKR1C3AKR1C1HTR6LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1990335-A1 | 17 BETA HSD TYPE 5 INHIBITOR | Astellas Pharma Inc. (JP) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | AKR1C3 189/4885AKR1C1 291/4885HTR6 1178/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | AKR1C3 109/4885AKR1C1 134/4885HTR6 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.